Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission – a case report - Report - MDSpire
Advertisement
Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission – a case report
Clinical Report: Integrative Oncology Combined with Systemic Treatments
Overview
This case report details the successful application of an integrative oncology protocol in a 75-year-old male with advanced bladder cancer, leading to significant symptomatic relief and normalization of cancer-related biomarkers. The findings suggest that combining systemic cancer therapies with complementary approaches may enhance clinical outcomes and quality of life.
Background
Bladder cancer presents significant treatment challenges, particularly in older adults, due to high recurrence rates and treatment-related toxicity. Current management strategies often focus on genetic factors, but emerging evidence suggests that metabolic dysfunctions also play a critical role in cancer progression. Integrative oncology approaches that address both genetic and metabolic aspects may offer a more comprehensive treatment strategy.
Data Highlights
No numerical data available in the article.
Key Findings
The patient demonstrated excellent tolerance to an integrative oncology protocol combining systemic therapies and complementary treatments.
Significant symptomatic relief was observed, alongside normalization of cancer-related biomarkers.
Metabolic optimization was achieved, with stable residual metabolic activity noted on PET-CT after six months.
Quality of life measures improved substantially during the treatment period.
Prognostic indices indicated enhanced survival potential following the integrative treatment approach.
Clinical Implications
The findings highlight the potential benefits of integrating metabolic therapies and complementary approaches with conventional cancer treatments. Clinicians may consider such integrative strategies to improve patient outcomes and quality of life in advanced bladder cancer cases.
Conclusion
This case report underscores the promising role of integrative oncology in managing advanced bladder cancer, warranting further investigation through larger, controlled studies to validate these findings.
